CVCharlotte A. Te Velde-Keyzer

Charlotte A. Te Velde-Keyzer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Charlotte A. Te Velde-Keyzer has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Posttransplant Dynamics of Serum T50 and Coronary Artery Calcium Scores Among Kidney Transplant Recipients

    by Amarens van der Vaart, Daan Kremer, Edward R. Smith, Rozemarijn Vliegenthart, Andreas Pasch, Jan-Luuk Hillebrands, Jeroen H.F. de Baaij, Stephan J.L. Bakker, Martin H. de Borst, Charlotte A. Te Velde-Keyzer, et al.


  • Open Access

    Short-term outcome after simultaneous pancreas-kidney transplantation with alemtuzumab vs. basiliximab induction: a single-center retrospective study

    by Tim D. A. Swaab, Robert A. Pol, Meindert J. Crop, Jan-Stephan F. Sanders, Stefan P. Berger, Hendrik S. Hofker, Stephan J. L. Bakker, Charlotte A. Te Velde-Keyzer

    During the COVID-19 pandemic our center adjusted the standard induction therapy for normal immunological risk simultaneous pancreas-kidney (SPK) transplantations from T-cell depletion by alemtuzumab (ALEM) to IL-2 receptor blocking by basiliximab (IL2R). Here, we analyze the impact of this change on 1 year post-transplantation outcomes. Thirty-six adult patients who underwent SPK transplantation between June 2015 and June 2023 were included, of whom 21 before February 2020 (ALEM) and 15 after February 2020 (IL2R). Patients were stratified into two groups based on the induction therapy received. One death occurred during the follow up period. A total of three pancreas and two kidney grafts were lost. No differences between kidney and pancreas graft function or rejection rates were observed. Patients receiving IL2R induction had significantly lower 30 day postoperative complication rates (34 vs. 46%, p = 0.03) and experienced fewer bacterial infections (< 6 months: 47 vs. 81%, p = 0.03). Additionally, lower rates of viral (including CMV) and fungal infections were observed. IL2R patients also had a significantly shorter hospital admission durations (14 vs. 30 days, p < 0.001). In conclusion, IL2R induction in SPK recipients was associated with similar short-term graft function and potentially improved outcomes compared to ALEM, warranting cautious interpretation due to sample size.


  • Highlights from the plenary session: cellular and molecular mechanisms of disease (I)

    by Jonas Zimmermann, Adrian Schreiber, Peter Heeringa, Charlotte A Te Velde—Keyzer

    In this plenary session of the Vasculitis Workshop 2024, pioneering translational research on autoimmune vasculitis, particularly ANCA-associated vasculitis (AAV), was presented, highlighting advancements in our understanding of disease mechanisms and promising therapeutic prospects. Advances in elucidating molecular pathways, such as IL-17 and IFN-I, pave the way for specific treatments. Preclinical studies have revealed the gut microbiome's role in the pathogenesis of MPO-AAV and demonstrate the therapeutic potential of dietary interventions. Furthermore, research into the protective role of Tregs has shed light on potential new targets for therapeutic interventions. Innovative approaches, such as CAR-T cell therapy and Deoxy Mab DX-1/DX-3, show significant promise in mitigating AAV pathology. These advancements underscore the transformative potential of translational research. By enhancing our understanding of disease mechanisms, these findings pave the way for the development of personalized and effective therapies, ultimately enhancing patient outcomes.

  • Open Access

    Calciprotein particle counts associate with vascular remodelling in chronic kidney disease

    by Lian Feenstra, Melanie Reijrink, Andreas Pasch, Edward R Smith, Lotte M Visser, Marian Bulthuis, Monique E Lodewijk, Mirjam F Mastik, Marcel J W Greuter, Riemer H J A Slart, et al.

    Calciprotein particles (CPPs) are circulating calcium and phosphate nanoparticles associated with development of vascular calcification (VC) in chronic kidney disease (CKD). Although recent studies have been focusing on associations of CPPs with presence of VC in CKD, insights in the underlying processes and mechanisms by which CPPs might aggravate VC and vascular dysfunction in vivo are currently lacking. Here, we assessed overall burden of abdominal VC in healthy kidney donors and CKD patients, and subsequently performed transcriptome profiling in vascular tissue obtained from these subjects, linking outcome to CPP counts and calcification propensity. Calcification scores were quantified in renal arteries, iliac arteries and abdominal aorta, using computed tomography (CT) scans of kidney donors and CKD patients. Vascular tissue was collected from kidney donors (renal artery) and CKD patients (iliac artery), after which bulk RNA sequencing and gene set enrichment analysis (GSEA) was performed on a subset of patients. Calcification propensity (crystallization time, T50) was measured using nephelometry, and CPP counts with microparticle flow cytometric analysis. Increased calcification scores (based on CT) were found in CKD patients compared to kidney donors. Transcriptome profiling revealed enrichment for processes related to endothelial activation, inflammation, extracellular matrix (ECM) remodelling and ossification in CKD vascular biopsies compared to kidney donors. Calcification propensity was increased in CKD, as well as CPP counts, of which the latter significantly associated with markers of vascular remodelling. Our findings reveal that CKD is characterized by systemic VC with increased calcification propensity and CPP counts. Transcriptome profiling showed altered vascular gene expression with enrichment for endothelial activation, inflammation, ECM remodelling and ossification. Moreover, we demonstrate for the first time that vascular remodelling processes are associated with increased circulating CPP counts. Interventions targeting CPPs are promising avenues for alleviating vascular remodelling and VC in CKD.


  • Open Access

    Preoperative cognitive performance and its association with postoperative complications in vascular surgery patients: A prospective study

    by Dagmar Goodijk, Louise B.D. Banning, Charlotte A. Te Velde-Keyzer, Barbara C. van Munster, Stephan J.L. Bakker, Barbara L. van Leeuwen, Clark J. Zeebregts, Robert A. Pol


  • Open Access

    Phase angle and donor type are determinants of coronary artery calcification in stable kidney transplant recipients at twelve months after transplantation

    by Fernanda G. Rodrigues, Megan S.M. Bruins, Rozemarijn Vliegenthart, Daan Kremer, Camilo G. Sotomayor, Ilja M. Nolte, Udo Douwe J. Mulder, Gerjan J. Navis, Ita Pfeferman Heilberg, Robert A. Pol, et al.


  • Open Access

    Effect of vitamin K supplementation on serum calcification propensity and arterial stiffness in vitamin K-deficient kidney transplant recipients: A double-blind, randomized, placebo-controlled clinical trial

    by Coby Eelderink, Daan Kremer, Ineke J. Riphagen, Tim J. Knobbe, Leon J. Schurgers, Andreas Pasch, D.J. Mulder, Eva Corpeleijn, Gerjan Navis, Stephan.J.L. Bakker, et al.


  • Open Access

    Reply to Janssen et al. Comment on “Kremer et al. Kidney Function-Dependence of Vitamin K-Status Parameters: Results from the TransplantLines Biobank and Cohort Studies. Nutrients 2021, 13, 3069”

    by Daan Kremer, Dion Groothof, Charlotte A. Keyzer, Coby Eelderink, Tim J. Knobbe, Adrian Post, Marco van Londen, Michele F. Eisenga, TransplantLines Investigators, Leon J. Schurgers, et al.

    We read with interest the comment by Janssen et al.

  • Open Access

    Kidney Function-Dependence of Vitamin K-Status Parameters: Results from the TransplantLines Biobank and Cohort Studies

    by Daan Kremer, Dion Groothof, Charlotte A. Keyzer, Coby Eelderink, Tim J. Knobbe, Adrian Post, Marco van Londen, Michele F. Eisenga, TransplantLines Investigators, Leon J. Schurgers, et al.

    High circulating dephosphorylated (dp) uncarboxylated (uc) matrix Gla protein (MGP) and uc osteocalcin (OC) concentrations are regarded as markers of vitamin K-deficiency. However, because MGP and OC are small molecules, they may potentially pass the glomerulus, and their blood concentrations may strongly depend on kidney function. However, many studies with vitamin K-status parameters do not structurally adjust for baseline kidney function, and detailed studies on kidney function-dependence of vitamin K-status markers are lacking. We therefore measured plasma dp-ucMGP using a chemiluminescent assay in 578 kidney transplant recipients (41% females, age 56 ± 13y, 7.5 (3.2 to 13.7)y after transplantation, eGFR 49 ± 17 mL/min/1.73 m2) participating in the prospective TransplantLines Cohort Studies. Additionally, dp-carboxylated MGP, ucOC and carboxylated OC were measured using ELISA in plasma of a subgroup of 60 participants. Finally, dp-ucMGP was measured in a separate cohort of 124 kidney transplant recipients before and three months after kidney transplantation. Dp-ucMGP positively correlated with creatinine, cystatin C, and negatively with eGFR (Spearman’s ρ 0.54, 0.60, and −0.54, respectively, p < 0.001 for all), and each 10 mL/min/1.73 m2 increase in eGFR was associated with a 14.0% lower dp-ucMGP. Additionally, dp-ucMGP strongly declined after kidney transplantation (pretransplantation: 1252 (868 to 1744) pmol/L to posttransplantation: 609 (451 to 914) pmol/L, p < 0.001). Proportions of dp-ucMGP over total MGP and ucOC over total OC were not associated with eGFR. This study highlights that dp-ucMGP is strongly associated with kidney function, and that levels strongly decrease after kidney transplantation. We therefore propose adequate adjustment for kidney function, or the use of kidney function-independent parameters such as proportion of uncarboxylated MGP or OC in the assessment of vitamin K-status in clinical practice and research.


  • Open Access

    Aorto-Iliac Artery Calcification and Graft Outcomes in Kidney Transplant Recipients

    by Stan Benjamens, Saleh Z. Alghamdi, Elsaline Rijkse, Charlotte A. Te Velde-Keyzer, Stefan P. Berger, Cyril Moers, Martin H. de Borst, Riemer H. J. A. Slart, Frank J. M. F. Dor, Robert C. Minnee, et al.

    While the association of vascular calcification with inferior patient outcomes in kidney transplant recipients is well-established, the association with graft outcomes has received less attention. With this dual-centre cohort study, we aimed to determine the clinical impact of recipient pre-transplant aorto-iliac calcification, measured on non-contrast enhanced computed tomography (CT)-imaging within three years prior to transplantation (2005–2018). We included 547 patients (61.4% male, age 60 (interquartile range 51–68) years), with a median follow-up of 3.1 (1.4–5.2) years after transplantation. The aorto-iliac calcification score (CaScore) was inversely associated with one-year estimated-glomerular filtration rate (eGFR) in univariate linear regression analysis (standard β −3.3 (95% CI −5.1 to −1.5, p < 0.0001), but not after adjustment for potential confounders, including donor and recipient age (p = 0.077). In multivariable Cox regression analyses, a high CaScore was associated with overall graft failure (p = 0.004) and death with a functioning graft (p = 0.002), but not with death-censored graft failure and graft function decline. This study demonstrated that pre-transplant aorto-iliac calcification is associated with one-year eGFR in univariate, but not in multivariable linear regression analyses. Moreover, this study underlines that transplantation in patients with a high CaScore does not result in earlier transplant function decline or worse death censored graft survival, although ongoing efforts for the prevention of death with a functioning graft remain essential.